-
公开(公告)号：EP1309569A2
公开(公告)日：2003-05-14
申请号：EP01973654.5
申请日：2001-08-17
申请人： Millennium Pharmaceuticals, Inc. , KYOWA HAKKO KOGYO CO., LTD. , Pandey, Anjali , Scarborough, Robert M. , Matsuno, Kenji , Ichimura, Michio , Nomoto, Yugi , Fujiwara, Shigeki , Ide, Shinichi , Tsukuda, Eiji , Irie, Junko , Oda, Shoji
发明人： PANDEY, Anjali , SCARBOROUGH, Robert, M. , MATSUNO, Kenji , ICHIMURA, Michio , NOMOTO, Yuji , FUJIWARA, Shigeki , IDE, Shinichi , TSUKUDA, Eiji , IRIE, Junko , ODA, Shoji
IPC分类号： C07D239/94 , C07D401/12 , C07D403/12 , A61K31/517 , A61P35/00
CPC分类号： C07D401/12 , C07D239/94 , C07D403/12
摘要： The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
-
公开(公告)号：EP1315715A1
公开(公告)日：2003-06-04
申请号：EP01964612.4
申请日：2001-08-17
申请人： Millennium Pharmaceuticals, Inc. , Kyowa Hakko Kogyo Co., Ltd , Pandey, Anjali , Scarborough, Robert M. , Matsuno, Kenji , Ichimura, Michio , Nomoto, Yugi , Ide, Shinichi , Tsukuda, Eiji , Irie, Junko , Oda, Shoji
发明人： PANDEY, Anjali , SCARBOROUGH, Robert, M. , MATSUNO, Kenji , ICHIMURA, Michio , NOMOTO, Yuji , IDE, Shinichi , TSUKUDA, Eiji , IRIE, Junko , ODA, Shoji
IPC分类号： C07D403/12 , C07D239/94 , C07D401/12
CPC分类号： C07D239/94 , A61K31/517 , C07D401/12 , C07D403/12
摘要： The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
-
公开(公告)号：EP1315715B1
公开(公告)日：2008-07-23
申请号：EP01964612.4
申请日：2001-08-17
发明人： PANDEY, Anjali , SCARBOROUGH, Robert, M. , MATSUNO, Kenji , ICHIMURA, Michio , NOMOTO, Yuji , IDE, Shinichi , TSUKUDA, Eiji , IRIE, Junko , ODA, Shoji
IPC分类号： C07D403/12 , C07D239/94 , C07D401/12
CPC分类号： C07D239/94 , A61K31/517 , C07D401/12 , C07D403/12
摘要： The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
-
公开(公告)号：EP1354882A1
公开(公告)日：2003-10-22
申请号：EP01271892.0
申请日：2001-12-27
发明人： MATSUNO, Kenji , UENO, K., c/o KYOWA HAKKO KOGYO CO., LTD , IWATA, Yasuhiro , MATSUMOTO, Y., c/o KYOWA HAKKO KOGYO CO., LTD , NAKANISHI, S., c/o KYOWA HAKKO KOGYO CO., LTD , TAKASAKI, K., c/o KYOWA HAKKO KOGYO CO., LTD , KUSAKA, H., c/o KYOWA HAKKO KOGYO CO., LTD , NOMOTO, Y., c/o KYOWA HAKKO KOGYO CO., LTD , OGAWA, A., c/o KYOWA HAKKO KOGYO CO., LTD
IPC分类号： C07D401/12 , C07D417/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D207/16 , C07D417/14 , A61K31/4709 , A61K31/4725 , A61K31/428 , A61K31/4439 , A61K31/496 , A61K31/4545 , A61K31/497 , A61K31/498 , A61K31/506 , A61K31/433 , A61K31/502 , A61K31/501
CPC分类号： C07D401/12 , C07D207/16 , C07D401/14 , C07D403/12 , C07D417/12 , C07D417/14
摘要： A compound represented by general formula (I):
A-B-D
A represents a substituted or unsubstituted 1-pyrrolidinyl group, a substituted or unsubstituted 3-thiazolidinyl group, a substituted or unsubstituted 1-oxo-3-thiazolidinyl group, or the like;
B represents a) a group represented by -(C(R 1 )(R 2 )) k CO- (wherein k represents an integer of from 1 to 6, R 1 and R 2 may be the same or different and each represents a hydrogen atom, a hydroxyl group, a halogen atom, or the like) or the like;
D represents -U-V [wherein U represents a substituted or unsubstituted piperazinediyl group or the like, V represents -E-R 7 (wherein E represents a single bond, -CO-, -C(=O)O-, or -SO 2 -; R 7 represents a hydrogen atom, a substituted or unsubstituted alkyl group, or the like)] > or a pharmacologically acceptable salt thereof.摘要翻译： 由通式（I）表示的化合物：A-B-D其中A表示取代或未取代的1-吡咯烷基，取代或未取代的3-噻唑烷基，取代或未取代的1-氧代-3-噻唑烷基等; B表示a）由 - （C（R 1）（R 2））（R 2）表示的基团kCO-（其中k表示1至6的整数，R 1和R 2可以是 相同或不同，各自表示氢原子，羟基，卤素原子等）等; D表示-UVΛ其中U表示取代或未取代的哌嗪二基等，V表示-ER 7（其中E表示单键，-CO - ， - C（= O）O-或-SO 2 - ; R 7表示氢原子，取代或未取代的烷基等）或其药理学上可接受的盐。
-
公开(公告)号：EP0668280A1
公开(公告)日：1995-08-23
申请号：EP94925621.8
申请日：1994-09-02
发明人： MACHII, Daisuke , MATSUNO, Kenji , KINOSHITA, Iwao , NOMOTO, Yuji , TAKAI, Haruki , OHNO, Tetsuji , NAGASHIMA, Ken , ISHIKAWA, Tomoko , YAMADA, Koji , ICHIMURA, Michio , KASE, Kiroshi
IPC分类号： C07D487/04 , A61K31/505
CPC分类号： C07D487/04
摘要： An imidazoquinazoline derivative represented by formula (I) or a pharmacologically acceptable salt thereof, wherein R 1 andR 2 may be the same or different from each other and each represents hydrogen, lower alkyl, lower alkenyl, aryl, etc.; R 3 represents hydrogen, lower alkyl, cycloalkyl, lower alkenyl, aryl, etc.; and X represents O or S. This compound has a potent and selective cCMP-specific PDE inhibitor activity and is useful for treating or mitigating cardiovascular diseases such as thrombosis, angina pectoris, hypertension and arteriosclerosis, asthma, and so forth.
摘要翻译： 由式（I）表示的咪唑并喹唑啉衍生物或其药学上可接受的盐，其中R 1和R 2可以相同或不同，各自表示氢，低级烷基，低级烯基，芳基等; R 3表示氢，低级烷基，环烷基，低级烯基，芳基等; X表示O或S.该化合物具有有效和选择性的cCMP特异性PDE抑制剂活性，可用于治疗或缓解心血管疾病如血栓形成，心绞痛，高血压和动脉硬化，哮喘等。
-
6.发明授权N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors 有权N-芳基 - {4- [7-（烷氧基）喹唑啉-4-基]哌嗪基}甲酰胺化合物作为PDGF受体阻断剂
公开(公告)号：EP1309569B1
公开(公告)日：2010-10-06
申请号：EP01973654.5
申请日：2001-08-17
发明人： PANDEY, Anjali , SCARBOROUGH, Robert, M. , MATSUNO, Kenji , ICHIMURA, Michio , NOMOTO, Yuji , IDE, Shinichi , TSUKUDA, Eiji , IRIE, Junko , ODA, Shoji
IPC分类号： C07D239/94 , C07D401/12 , C07D403/12 , A61K31/517 , A61P35/00
CPC分类号： C07D401/12 , C07D239/94 , C07D403/12
摘要： The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.02 秒)
